# Open-Label Study of Setmelanotide in Hypothalamic Obesity

> **NCT04725240** · PHASE2 · COMPLETED · sponsor: **Rhythm Pharmaceuticals, Inc.** · enrollment: 18 (actual)

## Conditions studied

- Hypothalamic Obesity

## Interventions

- **DRUG:** Setmelanotide

## Key facts

- **NCT ID:** NCT04725240
- **Lead sponsor:** Rhythm Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-06-07
- **Primary completion:** 2022-06-28
- **Final completion:** 2022-06-28
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2025-02-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04725240

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04725240, "Open-Label Study of Setmelanotide in Hypothalamic Obesity". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04725240. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*